These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 25268732)

  • 21. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety concerns regarding 5α reductase inhibitors for the treatment of androgenetic alopecia.
    Irwig MS
    Curr Opin Endocrinol Diabetes Obes; 2015 Jun; 22(3):248-53. PubMed ID: 25871957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride.
    Jung JY; Yeon JH; Choi JW; Kwon SH; Kim BJ; Youn SW; Park KC; Huh CH
    Int J Dermatol; 2014 Nov; 53(11):1351-7. PubMed ID: 24898559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia.
    Chiriacò G; Cauci S; Mazzon G; Trombetta C
    Andrology; 2016 Mar; 4(2):245-50. PubMed ID: 26763726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs.
    Pirozzi Farina F; Pischedda A
    Arch Ital Urol Androl; 2016 Jan; 87(4):312-6. PubMed ID: 26766804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia.
    Tsai TF; Choi GS; Kim BJ; Kim MB; Ng CF; Kochhar P; Jasper S; Brotherton B; Orban B; Lulic Z
    J Dermatol; 2018 Jul; 45(7):799-804. PubMed ID: 29667763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia.
    Tosti A; Pazzaglia M; Soli M; Rossi A; Rebora A; Atzori L; Barbareschi M; Benci M; Voudouris S; Vena GA
    Arch Dermatol; 2004 Jul; 140(7):857-8. PubMed ID: 15262698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-alpha reductase inhibitors and erectile dysfunction: the connection.
    Erdemir F; Harbin A; Hellstrom WJ
    J Sex Med; 2008 Dec; 5(12):2917-24. PubMed ID: 19090946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgenetic alopecia; drug safety and therapeutic strategies.
    Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
    Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dutasteride in Androgenetic Alopecia: An Update.
    Arif T; Dorjay K; Adil M; Sami M
    Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-therapies in androgenetic alopecia: review and clinical experiences.
    Rossi A; Anzalone A; Fortuna MC; Caro G; Garelli V; Pranteda G; Carlesimo M
    Dermatol Ther; 2016 Nov; 29(6):424-432. PubMed ID: 27424565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.
    Gur S; Kadowitz PJ; Hellstrom WJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):81-90. PubMed ID: 23173718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.
    Tanglertsampan C
    J Med Assoc Thai; 2012 Oct; 95(10):1312-6. PubMed ID: 23193746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
    Sato A; Takeda A
    J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
    Belknap SM; Aslam I; Kiguradze T; Temps WH; Yarnold PR; Cashy J; Brannigan RE; Micali G; Nardone B; West DP
    JAMA Dermatol; 2015 Jun; 151(6):600-6. PubMed ID: 25830296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guidelines on the use of finasteride in androgenetic alopecia.
    Mysore V; Shashikumar BM
    Indian J Dermatol Venereol Leprol; 2016; 82(2):128-34. PubMed ID: 26924401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology.
    Melcangi RC; Caruso D; Abbiati F; Giatti S; Calabrese D; Piazza F; Cavaletti G
    J Sex Med; 2013 Oct; 10(10):2598-603. PubMed ID: 23890183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistent sexual side effects of finasteride: could they be permanent?
    Irwig MS
    J Sex Med; 2012 Nov; 9(11):2927-32. PubMed ID: 22789024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia.
    Arca E; Açikgöz G; Taştan HB; Köse O; Kurumlu Z
    Dermatology; 2004; 209(2):117-25. PubMed ID: 15316165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.